Caliper Life Sciences (CALP)

TOP CONTRIBUTORS

Tom Park

www.zacks.com

Based in Hopkinton, MA, Caliper Life Sciences, Inc. (CALP) develops and commercializes life science instruments and related consumables and services for use in drug discovery and development and other life sciences research. Caliper makes specialized LabChips (roughly one-inch in diameter) that miniaturize, integrate, and automate laboratory functions, with the intention of enhancing the capabilities, and reducing the size of laboratories. Microfluidic chips, experiment-specific reagents, and related software are the main constituents of these specialized systems. The chips consist of a network of miniaturized, microfabricated channels through which chemicals and other fluids can be transported. After introducing reagents (chemical agents, dyes, or other materials required for biological experiments) automatically or by the user depending on the chip format, the instrument and specialized software (for scheduling, integration, and data management) after placement of the chip move the fluids in the network with pressure or electricity. Additionally, Caliper's high and ultra-high throughput screening systems, liquid handlers, advanced robotics (for automation), storage devices, and workstations (for dissolution, extraction, and evaporation) offer complete solutions to the pharmaceutical, biotechnology, chemical, agriculture, and food industries. The company s systems improve research efficiency by providing more accurate data at lower costs and higher speeds. The acquisition of NovaScreen in October 2005 expanded Caliper s service offerings. The acquisition of Xenogen in August 2006 expanded the company into the molecular imaging market. With Xenogen s imaging technologies, Caliper is able to provide an integrated package of products and services for both in vitro and in vivo research in drug discovery. In 2006, product revenue, service revenue (product support, validation services, drug discovery & development services, screening & profiling services, assay development services, & contract research & transgenic animal services), and license fees and contract revenue (from collaborations) contributed 64%, 22%, and 14%, respectively, to total revenue.

References